Release Date: February 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide some color on the expected loan portfolio growth for 2025 and 2026? A: We do not provide specific year-to-year guidance, but we aim for a 10% annual growth target. The performance at the end of 2025 will significantly influence 2026. We aim to buy as much public sector receivable as possible from high-quality customers. (Unidentified_2)
Q: Are you seeing any changes in the average payment time of the public administration in Italy? A: We haven't observed a significant shift in payment times. Our business tends to buy from parts of the distribution that do not pay as well as the average. For example, we buy less in Lombardy and more in Carrari. (Unidentified_2)
Q: Did the volumes in the last quarter include contributions from the new contract announced with the 9-month results? A: Yes, the volumes reflect the new contract in Italy, particularly in the NHS segment, not in the public administration. (Unidentified_2)
Q: When should we expect a decline in the stock of past due due to the recovery of the contagion portfolio? A: We have reduced the contagion portfolio by 20% over six months, and we expect this trend to continue. The reduction depends on our counterparts' willingness to pay. (Unidentified_2)
Q: Does your 2026 guidance include benefits from the late payment directive review? A: No, our guidance does not include any impact from the late payment directive review as it has not been enacted yet. (Unidentified_2)
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。